Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

VALERIO, Maria Rosaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.284
EU - Europa 2.985
AS - Asia 1.097
AF - Africa 18
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 10.399
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.271
IT - Italia 780
FI - Finlandia 540
DE - Germania 529
CN - Cina 508
SG - Singapore 444
UA - Ucraina 409
IE - Irlanda 172
GB - Regno Unito 162
SE - Svezia 118
RU - Federazione Russa 89
BE - Belgio 44
FR - Francia 39
IN - India 39
KR - Corea 34
RO - Romania 25
NL - Olanda 18
TR - Turchia 18
IR - Iran 16
GR - Grecia 15
CI - Costa d'Avorio 13
CA - Canada 10
HK - Hong Kong 10
CH - Svizzera 9
AT - Austria 8
ES - Italia 8
JP - Giappone 6
PL - Polonia 5
EU - Europa 4
LT - Lituania 4
AU - Australia 3
BG - Bulgaria 3
BR - Brasile 3
EG - Egitto 3
MX - Messico 3
PK - Pakistan 3
UZ - Uzbekistan 3
DZ - Algeria 2
ID - Indonesia 2
IL - Israele 2
LB - Libano 2
PH - Filippine 2
BY - Bielorussia 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EE - Estonia 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
IQ - Iraq 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MT - Malta 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
RS - Serbia 1
SA - Arabia Saudita 1
SI - Slovenia 1
TW - Taiwan 1
VE - Venezuela 1
VN - Vietnam 1
Totale 10.399
Salva come PNG Salva come JPEG
Città #
Fairfield 860
Chandler 538
Ashburn 501
Woodbridge 488
Wilmington 442
Singapore 366
Ann Arbor 360
Houston 357
Seattle 330
Cambridge 281
Jacksonville 228
Dublin 172
Medford 168
Des Moines 130
Palermo 108
Princeton 107
Altamura 104
Nanjing 97
Santa Clara 96
Lawrence 79
Boardman 68
New York 63
San Diego 59
Tulsa 58
Dearborn 55
Ludwigshafen am Rhein 53
Beijing 52
Brussels 44
London 38
Milan 37
Shenyang 37
Hebei 35
Jinan 35
Seongnam 33
Helsinki 32
Rome 29
Tianjin 28
Nanchang 27
Falls Church 26
Changsha 22
Jiaxing 20
Kerken 20
Venice 19
Munich 18
Kumar 17
Ningbo 17
Saint Petersburg 17
Berlin 16
Zhengzhou 15
Redwood City 14
Abidjan 13
San Mateo 13
Columbus 12
Guangzhou 12
Hangzhou 12
Izmir 12
Kitzingen 12
Los Angeles 12
San Paolo di Civitate 12
Washington 12
Verona 11
Kilburn 10
Tehran 10
Athens 9
Bremen 9
Frankfurt am Main 8
Lanzhou 8
Taiyuan 8
Taizhou 8
Chicago 7
Phoenix 7
Auburn Hills 6
Dottingen 6
Forest City 6
Kunming 6
Naples 6
Norwalk 6
Pune 6
Bologna 5
Florence 5
Fuzhou 5
Haikou 5
Kochi 5
Kowloon 5
Mazara del Vallo 5
Melfi 5
Moscow 5
Orange 5
Prescot 5
San Francisco 5
Xi'an 5
Catania 4
Central District 4
Den Haag 4
Falkenstein 4
Hefei 4
Lappeenranta 4
Ludwigshafen 4
Messina 4
Monreale 4
Totale 7.176
Salva come PNG Salva come JPEG
Nome #
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success 206
Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. 205
Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study 202
TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma 193
Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy 174
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients 173
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. 172
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma 163
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study 163
Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. 161
A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers 159
Clinical presentation and treatment of gastrointestinal stromal tumors. 156
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients 155
Adherence, compliance and persistence to oral antineoplastic therapy: A review focused on chemotherapeutic and biologic agents 154
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. 152
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers 150
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale 148
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. 144
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers 142
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). 140
Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): What has changed over the time? Preliminary results of the VICTOR-6 study 139
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial 133
TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome 132
Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor 132
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan 131
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. 130
Metastatic seeding of colon adenocarcinoma manifesting as synchronous breast and chest wall localization: report of a case. 130
Axillary Nodal Burden in Breast Cancer Patients With Pre-operative Fine Needle Aspiration-proven Positive Lymph Nodes Compared to Those With Positive Sentinel Nodes 125
Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients’ Need. Preliminary Results of the Victor-6 Study 124
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 124
Mutational analysis of BRCA1 gene in sicilian patients at risk for inherited breast and/or ovarian cancer: experience of reference centre for the biomolecular characterization of neoplasms and genetic screening of hereditary tumors. 123
Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. 123
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer 118
Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes 115
L'impiego del Tachosil in chirurgia epatica 114
Alexithymia and coping style in women going to visit in a breast cancer center. 110
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer 105
Analysis of Ki-ras mutations in stage I rectal carcinomas and respective regional lymphonodes 104
Gastric metastasis from breast cancer 104
A.Mutational analysis of BRCA1 in sicilian patients at risk for inherited of reference center for the biomolecular characterizaztion of neoplasm and genetic screening of hereditary tumors 103
Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience 103
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 102
Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration refractory Metastatic Adenocarcinoma of the Prostate Resistant to Docetaxel 99
A phase II study of capecitabine oxaliplatin chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes 98
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer 97
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA) 97
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer 95
Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study 95
Detection of free-circulating tumor DNA in plasma of patients with gastrointestinal cancer. 95
The prognostic role of TP53 mutations in advanced laryngeal squamous cell carcinoma (LSCC). 94
A Case of Follicular Tumor of Uncertain Malignant Potential (FT-UMP) with Glomeruloid Features Showing Capsular Mucinous Degeneration 94
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 93
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer. Proceeding of ICACT Fifteenth International Congress on Anticancer Treatment February 9th 12th 2004, Paris accepted for oral presentation 92
TP53 mutations and S-Phase fraction are independent prognostic indicators in locally advanced laryngeal squamous cell carcinoma 91
Studio di phase II: Docetaxel settimanale come seconda linea chemioterapia nel carcinoma prostatico avanzato. 91
Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study 91
TP53 mutations are not prognostic independent indicators in bladder cancer. 90
Mutational analysis of BRCA1 gene in sicilian patient at risk for inherited breast and/or ovarian cancer: experience of reference center the biomolecular characterization of neoplasm and genetic screening of hereditary tumors. 90
Alexithymia and copyng style in women going to visit in a breast cancer center 88
DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study 86
TP53 Mutation in exon 5 and S-Phase Fraction but not Mutations in Ras gene family and DNA-ploidy are Indipendent prognostic indicators in Laryngeal Squamous Cell Carcinoma 84
Low dose oral chemotherapy for hormone refractory prostate carcinoma estramustine phosphate versus estramustine phosphate and etoposide. A Randomized phase II study of GSTU foundation 80
Cardiotossicità e Cardioprotezione. 80
Current Role of Intraoperative Frozen Section Examination of Sentinel Lymph Node in Early Breast Cancer 80
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis 80
Weekly Paclitaxel (T) and pegylated liposomal Doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients.VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 79
Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated? 79
Epirubicina (EPI ) e Docetaxel (DOC ) come chemioterapia primaria ( C P ) nel trattamento del carcinoma mammario localmente avanzato ( CMLA ). VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 78
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 76
Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma 75
GRUPPO ONCOLOGICO ITALIA MERIDIONALE. NOVEL ASSOCIATION WITH GEMCITABINE AND DOCETAXEL AS SALVAGE CHEMOTHERAPY IN METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES: RESULT OF A NULTICENTER PHASE II STUDY 74
Pegylated Liposomal Doxorubicin and weekly paclitaxel as first line treatment in metastatic breast cancer 74
Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study 73
DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: Results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study 73
TP53 mutations are not prognostic indipendent indicators in bladder cancer 72
Lapatinib activity in a patient with encephalic metastases from trastuzumab-resistant her-2 positive breast cancer 72
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 71
RUOLO DELL’ECOCOLOR DOPPLER TISSUTALE NELLA VALUTAZIONE DELLA CARDIOTOSSICITÀ DA CHEMIOTERAPICI 70
Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: The G-Step trial 70
Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety 70
p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: A prospective study with a five-year follow-up 68
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data 65
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 64
Impressive objective response to nab-paclitaxel plus trastuzumab as fifth line therapy in aelderly her2-positive breast cancer patient 64
Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World 63
A phase 2 study of Oxaliplatin ( O ) – Capecitabine( C ) chemotherapy in metastatic breast cancer ( MBC ) patients pretreated with Anthracyclines and taxanes VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 61
The HERBA trial: a retrospective study on patients (pts) with HER2-positive (HER2+ve) breast cancer (BC) and brain metastases (BMs) 61
NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience 61
The Use of Gemcitabine in heavily pretreted breast cancer patients 57
STUDIO DI FASE II: DOCETAXEL SETTIMANALE COME SECONDA LINEA CHEMIOTERAPICA NEL CARCINOMA PROSTATICO AVANZATO 57
Terapia di seconda linea del carcinoma gastrico avanzato con la combinazione Irinotecan (Cpt 11) + Mitomicina (MMc). Studio di fase II del Gruppo Oncologico dell’Italia Meridionale (prot. GOIM 2106) VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 56
Relationship between the thymidylate synthase, p53 levels with the treatment by Cyclophosphamide, Metotrexate, 5-Fluorouracil chemotherapy (CMF) versus Docetaxel (TXT) in the locally advanced carcinoma of breast. 55
Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma? 52
Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Case Report 52
Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer 51
Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data 51
Mitoxantrone + Prednisone versus Taxotere + Prednisone nel trattamento del carcinoma prostatico ormonorefrattario (cpor ). Studio randomizzato di fase II del Gruppo Oncologico dell’Italia Meridionale (GOIM ). VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 47
RELATIONSHIP BETWEEN THYMIDYLATE SYNTHASE EXPRESSION AND p53 LEVELS WITH THE TREATMENT BY CYCLOPHOSPHAMIDE, 5-FLUOROURACIL CHEMOTHERAPY (CMF) VERSUS DOCETAXEL IN THE LOCALLY ADVANCED CARCINOMA OF THE BREAST. 46
Patients With Cancer and COVID-19: A WhatsApp Messenger-Based Survey of Patients' Queries, Needs, Fears, and Actions Taken 45
Relationship between thymidylate synthase expression and p53 levels with the treatment of cyclophsphamide, methotrexate, 5-fluorouracil chemotherapy ( CMF)versus docetaxel ( TXT) in locally advanced carcinoma of the breast 44
Totale 10.242
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.367
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.367
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.432 0 0 0 0 0 284 247 154 241 147 253 106
2020/20211.537 87 112 67 154 149 45 186 92 156 165 158 166
2021/20221.307 81 252 26 76 69 48 84 67 147 156 81 220
2022/20231.607 166 310 29 155 189 243 105 110 164 8 72 56
2023/2024994 41 127 80 72 62 138 181 55 25 19 64 130
2024/2025912 72 203 249 206 120 62 0 0 0 0 0 0
Totale 10.964